What is Verogen?
As a subsidiary of QIAGEN, Verogen operates at the intersection of biotechnology and criminal justice. The firm specializes in high-throughput NGS solutions, providing an integrated ecosystem of proprietary kits, automated systems, and analytical software. Their technology stack is engineered to address the most complex forensic challenges, including mitochondrial DNA analysis, kinship verification, and degraded sample processing. By streamlining laboratory workflows, Verogen enables forensic practitioners to achieve higher resolution data, thereby increasing the efficacy of human identification efforts in high-stakes investigative environments.
How much funding has Verogen raised?
Verogen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Verogen
PPP
Public-Private Partnership
What's next for Verogen?
With the successful deployment of this late-stage financing, Verogen is positioned to accelerate its research and development pipeline, focusing on the expansion of its NGS forensic platform. The strategic roadmap likely involves scaling global distribution networks and enhancing software capabilities to meet the increasing demand for rapid, accurate DNA analysis in the public sector. As the forensic industry shifts toward more sophisticated genomic tools, Verogen's integration with QIAGEN's broader diagnostic capabilities provides a robust foundation for sustained growth and technological dominance in the human identification market.
See full Verogen company page
